Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models

Fig. 3

Molecular arrangements associated to CRM1 inhibition: a-c CRM1 and Cyclin D1 nuclear accumulation. a Western blots for the nuclear expression of cyclin D1 and CRM1 in PC3 cells treated with 100 nM KPT-330 for 4, 8, 12 and 24 hrs (early events); b Western blots for the cytoplasmic expression of cyclin D1 and CRM1 in PC3 cells treated with KPT-330 for 24, 48 or 72 hr and and immunocytochemical evaluation for CRM1 in the same conditions (late events) and c immunocytochemical evaluation for cyclin D1 expression in PC3 cells treated with 100 nM KPT-330 for 8 (T8), 24 (T24) and 72 (T72) hrs (late events). d Western blots for nuclear expression of Foxo proteins, p21, p27, cyclin E, cdk2, cyclin B1 and Cdk1 in PC3 cells treated with 100 nM KPT-330 for 2, 4, 8 and 12 hrs (early events). e Immunocytochemical evaluation for Foxo3a expression in 22rv1 cells treated with 100 nM KPT-330 for 2 (T2), 8 (T8) and 12 (T12) hrs (early events). f Western blots for nuclear expression of p53 and MDM2 in AR+/p53wt 22rv1 cells treated with 100 nM KPT-330 for 4, 8, 12 and 24 hrs (Early events). g Western blot for AR nuclear expression in 22rv1 cells treated with 100 nM KPT-330 for 2, 4, 8 and 12 hr (early events) and h western blot for AR nuclear expression in 22rv1 cells treated with 100 nM KPT-330 for 8 (T8), 24 (T24) and 72 (T72) hrs (late events). Nuclear expression was normalized to lamin whereas cytosolic expression was normalized to β-actin

Back to article page
\